{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:04:49Z","timestamp":1761901489305,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.msard.2019.101489","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T02:58:07Z","timestamp":1572922687000},"page":"101489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8701-5413","authenticated-orcid":false,"given":"C.E.P.","family":"van Munster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.F.","family":"Kalkers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Killestein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.M.J.","family":"Uitdehaag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2019.101489_bib0001","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.apmr.2012.01.008","article-title":"Limb apraxia in multiple sclerosis: prevalence and impact on manual dexterity and activities of daily living","volume":"93","author":"Kamm","year":"2012","journal-title":"Arch. Phys. Med. Rehabil."},{"issue":"2","key":"10.1016\/j.msard.2019.101489_bib0002","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1185\/03007990903500649","article-title":"Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS","volume":"26","author":"Salter","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"issue":"9","key":"10.1016\/j.msard.2019.101489_bib0003","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1007\/s00415-008-0910-y","article-title":"Employment in multiple sclerosis. Exiting and re-entering the work force","volume":"255","author":"Julian","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2019.101489_bib0004","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/NDT.S10469","article-title":"Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis","volume":"7","author":"Hayes","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"10.1016\/j.msard.2019.101489_bib0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.7224\/1537-2073.2013-023","article-title":"A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis","volume":"16","author":"Goodman","year":"2014","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2019.101489_bib0006","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jns.2015.11.035","article-title":"Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with multiple sclerosis","volume":"360","author":"Savin","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.msard.2019.101489_bib0007","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2013.11.011","article-title":"Long-term effects of dalfampridine in patients with multiple sclerosis","volume":"337","author":"Ruck","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2019.101489_bib0008","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.clineuro.2015.08.023","article-title":"Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients","volume":"139","author":"Pavsic","year":"2015","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"1\u20132","key":"10.1016\/j.msard.2019.101489_bib0009","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jns.2015.06.008","article-title":"Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders","volume":"356","author":"Lo","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2019.101489_bib0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.msard.2016.07.019","article-title":"Effect of slow release-Fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study","volume":"10","author":"Jensen","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"14","key":"10.1016\/j.msard.2019.101489_bib0011","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1177\/1352458514533844","article-title":"Changes in cognition, arm function and lower body function after slow-release fampridine treatment","volume":"20","author":"Jensen","year":"2014","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.msard.2019.101489_bib0012","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00415-015-7797-1","article-title":"Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life","volume":"262","author":"Allart","year":"2015","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2019.101489_bib0013","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/2229-516X.157148","article-title":"Real world data: additional source for making clinical decisions","volume":"5","author":"Mahajan","year":"2015","journal-title":"Int. J. Appl. Basic Med. Res."},{"issue":"10","key":"10.1016\/j.msard.2019.101489_bib0014","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1177\/1352458517720043","article-title":"Fampridine response in MS patients with gait impairment in a real-world setting: need for new response criteria?","volume":"24","author":"Rodriguez-Leal","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.101489_bib0015","first-page":"75","article-title":"Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases","volume":"4","author":"Prugger","year":"2013","journal-title":"Patient Relat. Outcome Meas."},{"issue":"3","key":"10.1016\/j.msard.2019.101489_bib0016","article-title":"Objective and subjective measures of dalfampridine efficacy in clinical practice","volume":"4","author":"Klineova","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"8","key":"10.1016\/j.msard.2019.101489_bib0017","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1212\/WNL.58.8.1294","article-title":"Quantitative functional measures in MS: what is a reliable change?","volume":"58","author":"Schwid","year":"2002","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2019.101489_bib0018","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1177\/1352458516680749","article-title":"Identification and validation of clinically meaningful benchmarks in the 12-item multiple sclerosis walking scale","volume":"23","author":"Goldman","year":"2017","journal-title":"Mult. Scler."},{"issue":"21","key":"10.1016\/j.msard.2019.101489_bib0019","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1212\/01.wnl.0000436065.97642.d2","article-title":"Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world","volume":"81","author":"Goldman","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.101489_bib0020","article-title":"Identifying an important change estimate for the multiple sclerosis walking scale-12 (MSWS-12v1) for interpreting clinical trial results","volume":"1","author":"Mehta","year":"2015","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"7","key":"10.1016\/j.msard.2019.101489_bib0021","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1177\/1352458510370464","article-title":"Progression on the multiple sclerosis functional composite in multiple sclerosis: what is the optimal cut-off for the three components?","volume":"16","author":"Bosma","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.101489_bib0022","unstructured":"Anon [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fampyra."},{"issue":"Pt 5","key":"10.1016\/j.msard.2019.101489_bib0023","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/brain\/122.5.871","article-title":"Development of a multiple sclerosis functional composite as a clinical trial outcome measure","volume":"122","author":"Cutter","year":"1999","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.msard.2019.101489_bib0024","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.60.1.31","article-title":"Measuring the impact of MS on walking ability: the 12-Item MS walking scale (MSWS-12)","volume":"60","author":"Hobart","year":"2003","journal-title":"Neurology"},{"issue":"20","key":"10.1016\/j.msard.2019.101489_bib0025","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1080\/09638288.2016.1213898","article-title":"Measurement properties of the arm function in multiple sclerosis questionnaire (AMSQ): a study based on classical test theory","volume":"39","author":"van Leeuwen","year":"2017","journal-title":"Disabil. Rehabil."},{"key":"10.1016\/j.msard.2019.101489_bib0026","article-title":"minimal clinically important difference of improvement on the arm function in multiple sclerosis questionnaire (AMSQ)","author":"van Munster","year":"2018","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2019.101489_bib0027","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clinph.2016.10.088","article-title":"Fampridine treatment and walking distance in multiple sclerosis: a randomised controlled trial","volume":"128","author":"Pickering","year":"2017","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.msard.2019.101489_bib0028","article-title":"Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis","author":"Filli","year":"2018","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2019.101489_bib0029","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrneurol.2017.171","article-title":"Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting","volume":"14","author":"Tur","year":"2018","journal-title":"Nat. Rev. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103481930478X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103481930478X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:47:21Z","timestamp":1761900441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103481930478X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":29,"alternative-id":["S221103481930478X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.101489","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.101489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101489"}}